Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma.

NCT05776407 is registered in ClinicalTrials.gov with Chongqing University Cancer Hospital as lead sponsor.

NCT NCT05776407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma.
Lead sponsor
Chongqing University Cancer Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2023
Completion date
November 30, 2024
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory or relapsed b cell lymphoma